Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs NuuVim
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · NuuVim: August 2026
vs
Verdict59/ 100
Grade C · #394NuuVim
NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
Visit NuuVimThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 59/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. NuuVim still earns its place — low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results60
92
Real-world results60
97Price honesty50
97
Price honesty50
96Prescriber access49
96
Prescriber access49
88Formulary choice92
88
Formulary choice92
95Cancellation fairness56
95
Cancellation fairness56
93Member support54
93
Member support54
Price, coverage & features
| Metric | CoreAge Rx | NuuVim |
|---|---|---|
| Verdict Score | 94/100 | 59/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | $149/mo | From $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NuuVim
What we like
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
The caveats
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Visit NuuVim Read the full NuuVim review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for NuuVim does the reverse.
More on CoreAge Rx
More on NuuVim
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.